Global Exocrine Pancreatic Insufficiency Treatment Market to Grow at a CAGR of 8.27% During 2024-2032, Driven by the Positive Results Shown by Pancreatic Enzyme Replacement Therapy (PERT)

North America is expected to hold a significant share in the overall market growth of exocrine pancreatic insufficiency treatment. This can be associated with a large percentage of geriatric population, huge investments into research and drug development (R&D) projects, and the growth of the healthcare sector in the region. In addition to this, the increasing presence of diabetes due to unhealthy eating habits, rising awareness regarding EMI, and inflating disposable incomes are further predicted to have a positive influence over the regional market. Apart from this, pancreatic enzyme replacement therapy (PERT) aids in the digestion and the absorption of fats. This is expected to result in a substantial share of this segment in the overall market over the forecast period. The dominance of the segment can further be associated with its status as a conventional therapy. PERT is recommended to patients with EPI witnessing weight loss and malnutrition.

AzurRx Biopharma (NASDAQ: AZRX), a leading player in the global market for exocrine pancreatic insufficiency treatment in August 2021, announced positive results from its Phase 2 combination trial evaluating MS1819 along with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis (CF). The study demonstrated positive improvements in weight gain and other secondary endpoints. AzurRx is now developing a new enteric-coated microbead formulation for MS1819 and plans to initiate a bridging study in 2022 evaluating the formulation as a single-agent therapy. Such developments by leading market players are enhancing the growth of the market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Disease Management, Diagnosis, and Region:

• On the basis of disease management, the market can be divided into nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle modifications approach.

• On the basis of diagnosis, the market can be categorised into magnetic resonance imaging (MRI), CT scanning, endoscopic ultra-sonography (EUS), and blood tests, among others.

• The major regional markets for the product include North America, Latin America, Europe, the Asia Pacific, and the Middle East and Africa.

Key Findings of the Report:

• The market is being driven by the increasing prevalence of chronic pancreatic and cystic fibrosis amongst the geriatric populations and young children leading to the exocrine pancreatic insufficiency disorder.

• Surging awareness regarding the impact of exocrine pancreatic insufficiency on human health resulting in disturbances in normal growth, reduced life expectancy, and lowered immunity levels has stimulated the growth of the market.

• The market growth can be attributed to the large-scale investments into research and drug development (R&D) projects in the pharmaceutical sector.

• Pancreatic enzyme replacement therapy (PERT) aids the digestion and absorption of fats, which is boosting the market growth.

Key Offerings of the Report:

• The EMR report gives an overview of the global exocrine pancreatic insufficiency treatment industry for the periods (2018-2023) and (2024-2032).

• The report also offers historical (2018-2023) and forecast (2024-2032) markets for disease management, diagnosis, and major regions of exocrine pancreatic insufficiency treatment.

• The report analyses market dynamics, covering the key demand and price indicators in the market along with an assessment of the SWOT and Porter’s Five Forces Model.

The major players in the global exocrine pancreatic insufficiency treatment market are AbbVie Inc., Janssen Global Services, LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc, Cilian AG, Anthera Pharmaceuticals, Inc., Allergan plc., First Wave BioPharma, Inc. (AzurRx), and Aptalis Pharma Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.